ReviewThe Psychiatric clinics of North America2023
The Individual and Societal Burden of Treatment-Resistant Depression: An Overview.
Review in The Psychiatric clinics of North America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 15 citations in OpenAlex.
- Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD.European psychiatry : the journal of the Association of European Psychiatrists · 2026Trial
- The Paradox of Performativity: Latent Depression as a Crisis in the Contemporary Psychosocial Context.International journal of mental health nursing · 2026Article
- Review
- Cognition-Modulated EEG Signatures and Clinical Features in Major Depressive Disorder: A Machine Learning-Based Exploratory Study.Alpha psychiatry · 2026Article
- Screening for depression risk via smartphone narratives with fully fine-tuned WavLM.Scientific reports · 2026Article
- Ginsenoside Rh2 Protects Against Glutamate-Induced Neurotoxicity in PC12 Cells via Activation of the VEGF-mediated PI3K/Akt/mTOR Signaling Pathway.Neurochemical research · 2026Article
- Characterizing Illness Course to Understand the Role of Inflammation on Brain Structure and Function in Individuals With Depression.Biological psychiatry · 2026Article
- A multicenter randomized clinical trial of portable transcranial alternating current stimulation for major depressive disorder.NPJ digital medicine · 2026Article
- Vitamin D deficiency, depression severity, and suicide risk: evidence from patients with major depressive disorder.Turkish journal of medical sciences · 2026Article
- Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders.European archives of psychiatry and clinical neuroscience · 2025Article
- Association of miR-17-92 rs9588884 gene polymorphism with cognitive impairment in depression.Molecular biology reports · 2025Article
- Mechanisms Underlying Treatment-Resistant Depression: Exploring Sex-Based Biological Differences.Journal of neurochemistry · 2025Review
- Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.Drugs · 2025Review
- Review
- A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)?Pharmaceuticals (Basel, Switzerland) · 2025Article
- Observational
- Exploring cariprazine as a treatment option for varied depression symptom clusters.Frontiers in psychiatry · 2024Review
- Treatment-Resistant Depression (TRD): Is the Opioid System Involved?International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Major depressive disorder is characterized by depressed mood and/or anhedonia with neurovegetative symptoms and neurocognitive changes affecting an individual's functioning in multiple aspects of life. Treatment outcomes with commonly used antidepressants remain suboptimal. Treatment-resistant depression (TRD) should be considered after inadequate improvement with two or more antidepressant treatments of adequate dose and duration. TRD has been associated with increased disease burden including higher associated costs (both socially and financially) affecting both the individual and society. Additional research is needed to better understand the long-term burden of TRD to both the individual and society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.